Establishment Labs (NASDAQ:ESTA) Stock Rating Lowered by Wall Street Zen

Establishment Labs (NASDAQ:ESTA) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

Other analysts have also recently issued reports about the stock. Citigroup decreased their price target on shares of Establishment Labs from $81.00 to $74.00 and set a “neutral” rating for the company in a research report on Wednesday, March 11th. Stephens boosted their price objective on Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. BTIG Research upped their target price on Establishment Labs from $86.00 to $88.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday, December 29th. Finally, JPMorgan Chase & Co. raised their target price on Establishment Labs from $71.00 to $80.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $86.86.

Establishment Labs Trading Down 7.7%

Shares of ESTA stock opened at $55.31 on Friday. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of -31.79 and a beta of 0.91. The company has a quick ratio of 2.00, a current ratio of 3.04 and a debt-to-equity ratio of 10.51. Establishment Labs has a fifty-two week low of $26.56 and a fifty-two week high of $83.31. The firm’s 50 day moving average price is $68.98 and its two-hundred day moving average price is $61.88.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.13. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The company had revenue of $64.62 million during the quarter, compared to analyst estimates of $63.80 million. During the same quarter in the prior year, the business earned ($1.19) earnings per share. The business’s quarterly revenue was up 45.2% compared to the same quarter last year. On average, analysts anticipate that Establishment Labs will post -2.41 EPS for the current year.

Insider Buying and Selling

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 33,925 shares of the company’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $60.39, for a total value of $2,048,730.75. Following the completion of the transaction, the director directly owned 1,223,579 shares of the company’s stock, valued at $73,891,935.81. This represents a 2.70% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 11.09% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Geode Capital Management LLC lifted its stake in shares of Establishment Labs by 1.2% in the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock worth $1,105,000 after acquiring an additional 299 shares in the last quarter. Patriot Financial Group Insurance Agency LLC grew its stake in Establishment Labs by 5.8% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 6,375 shares of the company’s stock valued at $261,000 after purchasing an additional 350 shares in the last quarter. Handelsbanken Fonder AB increased its holdings in Establishment Labs by 7.3% during the 4th quarter. Handelsbanken Fonder AB now owns 8,800 shares of the company’s stock worth $641,000 after purchasing an additional 600 shares during the last quarter. Swiss National Bank increased its holdings in Establishment Labs by 1.8% during the 4th quarter. Swiss National Bank now owns 34,200 shares of the company’s stock worth $2,492,000 after purchasing an additional 600 shares during the last quarter. Finally, Kestra Advisory Services LLC acquired a new position in shares of Establishment Labs in the 4th quarter valued at approximately $47,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.